视频 丨 武汉海特生物制药股份有限公司董事会秘书杨坤

Core Viewpoint - The future direction of the company is optimistic towards Cell and Gene Therapy (CGT), supported by the successful commercialization of targeted drugs such as monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates [2] Group 1 - The technological evolution from monoclonal antibodies to bispecific antibodies and ADCs demonstrates the feasibility of CGT [2] - The future commercial value of CGT is expected to be realized [2]